【结 构 式】 |
【分子编号】41351 【品名】di(tert-butyl) (2R)-2-[[(4S)-4-amino-5-(tert-butoxy)-5-oxopentanoyl]amino]pentanedioate 【CA登记号】 |
【 分 子 式 】C22H40N2O7 【 分 子 量 】444.56888 【元素组成】C 59.44% H 9.07% N 6.3% O 25.19% |
与该中间体有关的原料药合成路线共 1 条
合成路线1
该中间体在本合成路线中的序号:(XV)Benzoic acid derivative (XIII) was converted to pentafluorophenyl ester (XIV) by DCC-mediated coupling with pentafluorophenol. Then, condensation with tri-tert-butyl L-gamma-glutamyl-D-glutamate (XV) furnished the corresponding amide (XVI). The tert-butyl esters of (XVI) were finally cleaved by treatment with trifluoroacetic acid.
【1】 Boyle, F.; Crook, J.W.; Matusiak, Z.S. (AstraZeneca plc; BTG plc); Tricyclic cpds. with pharmaceutical activity. EP 0667864; GB 2272217; JP 1996505838; US 5789417; WO 9411354 . |
中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
---|---|---|---|---|---|---|
(XIII) | 41349 | 4-[(2-methyl-4-oxo-4,6,7,8-tetrahydro-3H-cyclopenta[g]quinazolin-6-yl)(2-propynyl)amino]benzoic acid | C22H19N3O3 | 详情 | 详情 | |
(XIV) | 41350 | 2,3,4,5,6-pentafluorophenyl 4-[(2-methyl-4-oxo-4,6,7,8-tetrahydro-3H-cyclopenta[g]quinazolin-6-yl)(2-propynyl)amino]benzoate | C28H18F5N3O3 | 详情 | 详情 | |
(XV) | 41351 | di(tert-butyl) (2R)-2-[[(4S)-4-amino-5-(tert-butoxy)-5-oxopentanoyl]amino]pentanedioate | C22H40N2O7 | 详情 | 详情 | |
(XVI) | 41352 | di(tert-butyl) (2R)-2-[[(4S)-5-(tert-butoxy)-4-([4-[(2-methyl-4-oxo-4,6,7,8-tetrahydro-3H-cyclopenta[g]quinazolin-6-yl)(2-propynyl)amino]benzoyl]amino)-5-oxopentanoyl]amino]pentanedioate | C44H57N5O9 | 详情 | 详情 |
Extended Information